Fragmentation and Multifragmentation of 10.6A GeV Gold Nuclei

We present the results of a study performed on the interactions of 10.6A GeV gold nuclei in nuclear emulsions. In a minimum bias sample of 1311 interac- tions, 5260 helium nuclei and 2622 heavy fragments were observed as Au projec- tile fragments. The experimental data are analyzed with particular emphasis of target separation interactions in emulsions and study of criticalexponents. Multiplicity distributions of the fast-moving projectile fragments are inves- tigated. Charged fragment moments, conditional moments as well as two and three -body asymmetries of the fast moving projectile particles are determined in terms of the total charge remaining bound in the multiply charged projectile fragments. Some differences in the average yields of helium nuclei and heavier fragments are observed, which may be attributed to a target effect. However, two and three-body asymmetries and conditional moments indicate that the breakup mechanism of the projectile seems to be independent of target mass. We looked for evidence of critical point observable in finite nuclei by study the resulting charged fragments distributions. We have obtained the values for the critical exponents gamma, beta and tau and compare our results with those at lower energy experiment (1.0A GeV data). The values suggest that a phase transition like behavior, is observed.Comment: latex, revtex, 28 pages, 12 figures, 3tables, submitted to Europysics Journal

Clinical efficacy of dry nutritional treatment products for phenylketonuria in children, adults, and pregnant women: study results

N.A. Semenova1, G.V. Baydakova1, N.V. Nikitina2, V.K. Podolina2, E.Yu. Belyashova3,&nbsp;V.N. Kuznetsova3, E.M. Kochegurova4, L.P. Andreeva5, O.N. Khaylova5, S.I. Kutsev1 1Research Centre for Medical Genetics, Moscow, Russian Federation 2Clinical and Diagnostic Center “Protection of Health of Mother and Child”, Yekaterinburg, Russian Federation 3Orenburg Regional Clinical Hospital No. 2, Orenburg, Russian Federation 4E.M. Bakunina Regional Clinical Perinatal Center, Tver, Russian Federation 5Saratov Regional Children’s Clinical Hospital, Saratov, Russian Federation Abstract Aim: to assess the efficacy of domestic nutritional treatment products for phenylketonuria (PKU) in children, adults, and pregnant women. Patients and Methods: 46 patients with verified PKU were enrolled in this open-label multicenter prospective non-controlled study. Patients were allocated to the groups depending on nutritional treatment products which were prescribed according to the Clinical Guidelines of the Ministry of Health of Russian Federation. Clinical efficacy of the products was assessed according to the Good Clinical Practice guidelines based on clinical and laboratory tests. Results: all patients taken nutritional treatment products throughout the study. No dyspepsia, abnormal poop, or allergic reactions were reported. Most patients reported on more pleasant smell and odor of the products as compared with the products taken previously. At baseline, mean phenylalanine levels were within normal limits. After the treatment, phenylalanine levels were stable&nbsp; in all patients. Clinical and biochemical tests were within normal limits. Conclusion: dry nutritional treatment products are highly effective in children, adults, and pregnant women with PKU. Keywords: phenylketonuria, specialized food, phenylalanine, mixture, products. For citation: Semenova N.A., Baydakova G.V., Nikitina N.V. et al. Clinical efficacy of dry nutritional treatment products for phenylketonuria in children, adults, and pregnant women: study results. Russian Journal of Woman and Child Health. 2019;2(4):355–360. <br

Author Correction: Planar and van der Waals heterostructures for vertical tunnelling single electron transistors (Nature Communications, (2019), 10, 1, (230), 10.1038/s41467-018-08227-1)

10.1038/s41467-019-08910-xNature Communications10198

Planar and van der Waals heterostructures for vertical tunnelling single electron transistors

10.1038/s41467-018-08227-1Nature Communications10123